Coordinatore | THE UNIVERSITY OF NOTTINGHAM
Organization address
address: University Park contact info |
Nazionalità Coordinatore | United Kingdom [UK] |
Totale costo | 7˙866˙606 € |
EC contributo | 5˙961˙648 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2011-single-stage |
Funding Scheme | CP-FP-SICA |
Anno di inizio | 2011 |
Periodo (anno-mese-giorno) | 2011-11-01 - 2016-04-30 |
# | ||||
---|---|---|---|---|
1 |
THE UNIVERSITY OF NOTTINGHAM
Organization address
address: University Park contact info |
UK (NOTTINGHAM) | coordinator | 434˙441.00 |
2 |
GENOME RESEARCH LIMITED
Organization address
address: THE GIBBS BUILDING, EUSTON ROAD 215 contact info |
UK (LONDON) | participant | 1˙963˙929.60 |
3 |
ISLENSK ERFDAGREINING EHF
Organization address
address: Sturlugata 8 contact info |
IS (REYKJAVIK) | participant | 1˙424˙550.00 |
4 |
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
Organization address
address: KEPPEL STREET contact info |
UK (LONDON) | participant | 482˙450.00 |
5 |
"REPUBLICAN STATE ENTERPRISE WITH ECONOMIC MANAGEMENT SCIENTIFIC CENTRE OF OBSTETRICS, GYNECOLOGY AND PERINATOLOGY OF MINISTRY OF HEALTH"
Organization address
address: DOSTYK AVE 125 contact info |
KZ (ALMATY) | participant | 400˙420.00 |
6 |
IMMUNOLOGIYA INSTITUTI O'ZBEKISTONRESPUBLIKASI FANLAR AKADEMIYASI
Organization address
address: YA GULAMOV STREET 74 contact info |
UZ (TASHKENT) | participant | 300˙810.00 |
7 |
NASJONALT FOLKEHELSEINSTITUTT
Organization address
address: Lovisenberggata 8 contact info |
NO (OSLO) | participant | 280˙045.00 |
8 |
HELSINGIN YLIOPISTO
Organization address
address: YLIOPISTONKATU 4 contact info |
FI (HELSINGIN YLIOPISTO) | participant | 209˙761.20 |
9 |
UNIVERSITY OF GLASGOW
Organization address
address: University Avenue contact info |
UK (GLASGOW) | participant | 172˙983.60 |
10 |
UNIVERSITY OF LEEDS
Organization address
address: WOODHOUSE LANE contact info |
UK (LEEDS) | participant | 114˙048.00 |
11 |
RESPUBLIKA ISTISOSLASHTIRILGAN AKUSHERLIK VA GINEKOLOGIYA ILMIY-AMALIY TIBBIYOT MARKAZI
Organization address
address: MIRZO ULUGBEK 132-A contact info |
UZ (Tashkent) | participant | 107˙200.00 |
12 |
NORGES TEKNISK-NATURVITENSKAPELIGEUNIVERSITET NTNU
Organization address
address: HOGSKOLERINGEN 1 contact info |
NO (TRONDHEIM) | participant | 71˙010.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Pre-eclampsia, one of the most dangerous cardiometabolic complications of pregnancy, claims the lives of 50,000 mothers and almost one million babies annually. Pre-eclampsia and other hypertensive disorders of pregnancy remain the second most common cause of maternal death. The incidence of pre-eclampsia in Central Asian countries is over twice as high as in western Europe. Inter-population differences in genetic variants may be partly responsible for variation in predisposition to the condition. The AIMS of the InterPregGen consortium proposal are to establish sustainable and productive collaborative links between research groups in Central Asia (Kazakhstan and Uzbekistan) and Europe (Finland, Iceland, Norway, UK); and to identify and compare the genetic variants which predispose to pre-eclampsia. We shall achieve the first aim through scientific co-operation, and through training of Central Asian researchers in centres of excellence in Europe. We shall address the limited knowledge of genetic diversity in Central Asian populations by undertaking whole genome sequencing, analogous to the 1000 Genomes project. We will establish the first pre-eclampsia biobanks of DNA and plasma samples from a total of 4000 affected women, their partners and babies, and matched control samples from healthy pregnant women, in Kazakhstan and Uzbekistan. Existing genome-wide screening data, and data generated as part of this project, from a total of 10400 maternal cases and 7800 affected babies, will be used to identify pre-eclampsia susceptibility genes. We will maximise the information available by conducting meta-analyses of maternal and fetal datasets, and examining maternal-fetal gene interaction effects. By identifying genetic variants which predispose to pre-eclampsia we will gain insights into the underlying pathological mechanisms. This will generate novel hypotheses on the aetiology of pre-eclampsia, and provide targets for improved prediction, prevention and treatment'
An EU-funded project has designed the largest genetic study ever of women with pre-eclampsia, and their babies, in central Asia and Europe. Results are expected to deliver a predictive tool for the condition.
First Targeted Therapy to FIGHT Hemophagocytic Lymphohistiocytosis (HLH): A novel approach to HLH
Read MoreChronotherapeutic lifestyle intervention for diabetes and obesity to reset the circadian rhythm and improve cardiometabolic risk in the European working population
Read MoreTreatment of late onset bacterial sepsis caused by vancomycin susceptible bacteria in neonates and infants aged under three months
Read More